Teva Oncology offers the Comprehensive Oncology Reimbursement Expertise (CORE) program and the Teva Cares Foundation Patient Assistance Program to help patients while taking a Teva Oncology treatment (Table).
The Teva CORE program helps eligible patients, their caregivers, and healthcare professionals navigate the reimbursement process through a range of services, including benefit verification, coverage determination, prior authorizations, letters of medical necessity, and referrals to the Teva Cares Foundation.
For patients prescribed Granix, Herzuma, and Truxima, Teva CORE offers a Patient Savings Program.
To enroll your patient in the Teva CORE program, visit Teva CORE.
Teva Cares Foundation Patient Assistance Program
If your patient is uninsured or underinsured, they may be eligible to receive their prescribed Teva medication at no cost. Patients must meet certain financial and insurance coverage criteria to be eligible. Patient Assistance Program applications are available at Teva Cares Foundation Patient Assistance Program.
TABLE Teva Oncology/Supportive Care Drugs
Patient support programs
Bendeka (bendamustine hydrochloride)
Treatment of patients with chronic lymphocytic leukemia
Treatment of patients with indolent B-cell non-Hodgkin lymphoma progressing during/within 6 months of rituximab or a rituximab-containing regimen
To reduce severe neutropenia duration in patients aged ≥1 months with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Adjuvant treatment of HER2-overexpressing node-positive or -negative breast cancer, in combination with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; in combination with docetaxel and carboplatin; or as monotherapy after multimodality anthracycline-based therapy
First-line treatment of HER2-overexpressing metastatic breast cancer, in combination with paclitaxel, or as monotherapy in patients who received ≥1 chemotherapy regimens for metastatic disease
Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with cisplatin and capecitabine or 5-fluorouracil, in patients who have not received previous therapy for metastatic disease
Truxima (rituximab-abbs) Indications
Treatment of adults with relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent; treatment of previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; treatment of nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; treatment of previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens
Treatment of previously untreated and previously treated CD20-positive
CLL in combination with fludarabine and cyclophosphamide
Treatment, in combination with methotrexate, of adults with moderately to severely active rheumatoid arthritis who have inadequate response to ≥1 TNF antagonist therapies
Treatment of adults with granulomatosis with polyangiitis (Wegener granulomatosis) and microscopic polyangiitis, in combination with glucocorticoids